QuidelOrtho (QDEL) to Release Earnings on Wednesday

QuidelOrtho (NASDAQ:QDEL) is anticipated to issue its Q2 2026 results after the market closes on Wednesday, July 29th. Analysts expect the company to announce earnings of ($0.04) per share and revenue of $619.5370 million for the quarter. QuidelOrtho has set its FY 2026 guidance at 1.800-2.000 EPS. Individuals may review the information on the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Tuesday, August 4, 2026 at 5:00 PM ET.

QuidelOrtho (NASDAQ:QDEL) last issued its quarterly earnings data on Tuesday, May 5th. The company reported ($0.04) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.37 by ($0.41). QuidelOrtho had a positive return on equity of 4.25% and a negative net margin of 45.57%.The firm had revenue of $619.80 million for the quarter, compared to the consensus estimate of $665.23 million. During the same quarter in the prior year, the firm earned $0.74 EPS. The company’s revenue was down 10.5% on a year-over-year basis. On average, analysts expect QuidelOrtho to post $2 EPS for the current fiscal year and $2 EPS for the next fiscal year.

QuidelOrtho Price Performance

QuidelOrtho stock opened at $16.43 on Wednesday. The company has a market capitalization of $1.12 billion, a price-to-earnings ratio of -0.92 and a beta of 0.69. The company has a current ratio of 1.43, a quick ratio of 0.80 and a debt-to-equity ratio of 1.33. QuidelOrtho has a 12 month low of $9.92 and a 12 month high of $35.58. The stock’s 50 day moving average is $14.54 and its 200-day moving average is $18.91.

Analyst Upgrades and Downgrades

QDEL has been the topic of a number of research reports. Wall Street Zen raised QuidelOrtho from a “sell” rating to a “hold” rating in a report on Sunday, June 28th. JPMorgan Chase & Co. lifted their target price on QuidelOrtho from $11.00 to $12.00 and gave the stock an “underweight” rating in a report on Wednesday, July 1st. Citigroup boosted their target price on shares of QuidelOrtho from $13.00 to $18.00 and gave the company a “neutral” rating in a research report on Wednesday, July 8th. UBS Group restated a “neutral” rating and issued a $12.00 price target on shares of QuidelOrtho in a research note on Thursday, May 7th. Finally, Zacks Research raised shares of QuidelOrtho from a “strong sell” rating to a “hold” rating in a research report on Monday, June 15th. Four research analysts have rated the stock with a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Reduce” and an average target price of $13.62.

Institutional Investors Weigh In On QuidelOrtho

A number of large investors have recently added to or reduced their stakes in QDEL. California State Teachers Retirement System grew its position in QuidelOrtho by 1.2% during the 2nd quarter. California State Teachers Retirement System now owns 62,188 shares of the company’s stock worth $1,792,000 after acquiring an additional 725 shares during the last quarter. Global Retirement Partners LLC increased its holdings in QuidelOrtho by 3,691.7% in the 4th quarter. Global Retirement Partners LLC now owns 910 shares of the company’s stock worth $26,000 after purchasing an additional 886 shares in the last quarter. JPMorgan Chase & Co. increased its holdings in QuidelOrtho by 0.7% in the 4th quarter. JPMorgan Chase & Co. now owns 126,404 shares of the company’s stock worth $3,610,000 after purchasing an additional 903 shares in the last quarter. Larson Financial Group LLC raised its position in QuidelOrtho by 322.2% in the third quarter. Larson Financial Group LLC now owns 1,330 shares of the company’s stock valued at $39,000 after purchasing an additional 1,015 shares during the last quarter. Finally, Comerica Bank raised its position in QuidelOrtho by 1.8% in the third quarter. Comerica Bank now owns 77,921 shares of the company’s stock valued at $2,295,000 after purchasing an additional 1,349 shares during the last quarter. Institutional investors and hedge funds own 99.00% of the company’s stock.

QuidelOrtho Company Profile

QuidelOrtho is a global diagnostics company formed through the merger of Quidel Corporation and Ortho Clinical Diagnostics. The combined entity develops, manufactures and markets a broad portfolio of rapid and high-throughput diagnostic solutions across immunoassay, molecular diagnostics and transfusion medicine. Its offerings span point-of-care platforms for acute care testing as well as large-scale automated systems designed for clinical laboratories and blood banks.

The company’s product range includes rapid antigen and antibody tests for infectious diseases, molecular assays utilizing nucleic acid amplification technology, and integrated immunodiagnostic analyzers.